title: FDA perspective on the need for revised performance goals for evaluating stenting of femoropopliteal arteries.
authors.affiliation: Food and Drug Administration, Center for Devices and Radiological Health, Office of Device Evaluation, Silver Spring, Maryland.
authors.forename: Lindsay K
authors.initials: LK
authors.lastname: Pack
authors.forename: Donna C
authors.initials: DC
authors.lastname: Buckley
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Goode
authors.forename: Steven S
authors.initials: SS
authors.lastname: Brooks
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Lim
mesh_terms: D000497:Alloys; D057510:Endovascular Procedures / Q000295:instrumentation*; D005263:Femoral Artery; D006801:Humans; D058729:Peripheral Arterial Disease / Q000628:therapy*; D011150:Popliteal Artery; D015607:Stents
chemical_list: D000497:Alloys; C013616:nitinol